Wael Yared
Directeur Technique/Scientifique/R&D chez TECAN GROUP AG
Fortune : 876 374 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Andreas Wilhelm | M | 55 | 20 ans | |
Ulrich Kanter | M | 61 | 10 ans | |
Martin Brändle | M | 53 | 16 ans | |
Achim von Leoprechting | M | 56 | 11 ans | |
Daniel Marshak | M | 67 | 6 ans | |
Ingrid Pürgstaller | F | 44 | 4 ans | |
Ralf Griebel | M | 52 | 4 ans | |
Myra Eskes | F | - | 2 ans | |
Tania Micki | F | 52 | 4 ans | |
Erik Norström | M | 50 | 7 ans | |
Klaus Lun | M | 52 | 11 ans | |
Lukas Braunschweiler | M | 68 | 6 ans | |
Christa Kreuzburg | M | 65 | 11 ans | |
Günter Weisshaar | M | 64 | 21 ans | |
Oliver Fetzer | M | 60 | 13 ans | |
Karen Hübscher | M | 61 | 12 ans | |
Matthias Gillner | M | 57 | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Guy L. Mayer | M | 72 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | 3 ans |
Markus Schmid | M | 56 | 9 ans | |
Harry Wilcox | M | 69 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
Erik Walldén | M | 75 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
David Roy Martyr | M | 67 | 7 ans | |
Heinrich Fischer | M | 74 | 16 ans | |
John Ziolkowski | M | - |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
Rudolf Eugster | M | 59 | 18 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Suisse | 21 | 84,00% |
Etats-Unis | 4 | 16,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Wael Yared
- Réseau Personnel